Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma
1 Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, PR China
2 Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang 110001, PR China
3 The Third Center for Laboratory Technology and Experimental Medicine, China Medical University, Shenyang 110001, PR China
4 Department of Internal Medicine, Liaoning Cancer Hospital & Institute, Shenyang 110042, PR China
5 Department of Respiratory Medicine, Fengtian Hospital Affiliated to Shenyang Medical College, Shenyang 110024, PR China
6 Department of Pathology, 202 Hospital of Chinese PLA, Shenyang 110003, PR China
7 Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, PR China
8 Shenyang Center for Disease Control and Prevention, Shenyang 110031, PR China
BMC Cancer 2009, 9:439 doi:10.1186/1471-2407-9-439Published: 15 December 2009
Excision repair cross-complementing group 1 (ERCC1) and group 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) proteins play important roles in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of DNA repair genes are suspected to influence treatment effect and survival of cancer patients. This study aimed to investigate the relationship between polymorphisms in ERCC2, ERCC1 and XRCC1 genes and survival of non-smoking female patients with lung adenocarcinoma.
We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to evaluate SNPs in ERCC2, ERCC1 and XRCC1 genes among 257 patients.
The overall median survival time (MST) was 13.07 months. Increasing numbers of either ERCC1 118 or XRCC1 399 variant alleles were associated with shorter survival of non-smoking female lung adenocarcinoma patients (Log-rank P < 0.001). The adjusted hazard ratios (HRs) for individuals with CT or TT genotype at ERCC1 Asn118Asn were 1.48 and 2.67 compared with those with CC genotype. For polymorphism of XRCC1 399, the HRs were 1.28 and 2.68 for GA and AA genotype. When variant alleles across both polymorphisms were combined to analysis, the increasing number of variant alleles was associated with decreasing overall survival. Using the stepwise Cox regression analysis, we found that the polymorphisms in ERCC1 and XRCC1, tumor stage and chemotherapy or radiotherapy status independently predicted overall survival of non-smoking female patients with lung adenocarcinoma.
Genetic polymorphisms in ERCC1 and XRCC1 genes might be prognostic factors in non-smoking female patients with lung adenocarcinoma.